Abstract Search

ea0099p215 | Adrenal and Cardiovascular Endocrinology | ECE2024

Incidence of adrenal crisis in Congenital Adrenal Hyperplasia (CAH) patients during a prospective monitored long-term study of modified-release hydrocortisone (MRHC) capsules, (Efmody)

John M. Ross Richard , Merke Deborah P , Mallappa Ashwini , Arlt Wiebke , DeLaPerriere AudeBrac , Hirschberg Angelica , Newell-Price John DC , Prete Alessandro , Rees Aled , Reisch Nicole , Quinkler Marcus , Touraine Philippe A , Maltby Kerry , Quirke Jo , Aslam Naila , Coope Helen , Porter John

Background: Adrenal crisis is the leading cause of excess mortality in patients with CAH1. Retrospective studies report an adrenal crisis incidence of 5-10/100 patient years (PY), with mortality 0.5/100 PY2. Modified-release hydrocortisone (MRHC) capsules, (Efmody), replicate cortisol diurnal rhythm and improve androgen control in CAH compared to standard glucocorticoid therapy2. Here, we report the incidence of adrenal crisis in CAH patients f...

1 shares

Endocrine Abstracts

Incidence of adrenal crisis in Congenital Adrenal Hyperplasia (CAH) patients during a prospective monitored long-term study of modified-release hydrocortisone (MRHC) capsules, (Efmody)

BiosciAbstracts